MA55872A - Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires - Google Patents

Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires

Info

Publication number
MA55872A
MA55872A MA055872A MA55872A MA55872A MA 55872 A MA55872 A MA 55872A MA 055872 A MA055872 A MA 055872A MA 55872 A MA55872 A MA 55872A MA 55872 A MA55872 A MA 55872A
Authority
MA
Morocco
Prior art keywords
treatment
ocular diseases
sema3a antibodies
sema3a
antibodies
Prior art date
Application number
MA055872A
Other languages
English (en)
French (fr)
Inventor
Rachel Rebecca Barrett
Kristin Laura Bovat
Rajkumar Ganesan
Priyanka Gupta
Fei Han
Dongmei Liu
Juergen Prestle
Sanjaya Singh
Leo Thomas
Sathyadevi Venkataramani
Helen Haixia Wu
Nina Zippel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA55872A publication Critical patent/MA55872A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA055872A 2019-05-09 2020-05-08 Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires MA55872A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19173454 2019-05-09

Publications (1)

Publication Number Publication Date
MA55872A true MA55872A (fr) 2022-03-16

Family

ID=66476463

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055872A MA55872A (fr) 2019-05-09 2020-05-08 Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires

Country Status (28)

Country Link
US (3) US11267880B2 (enExample)
EP (1) EP3966239A1 (enExample)
JP (2) JP7314310B2 (enExample)
KR (1) KR20220007128A (enExample)
CN (1) CN113795509A (enExample)
AR (1) AR122266A1 (enExample)
AU (1) AU2020267874A1 (enExample)
BR (1) BR112021019854A2 (enExample)
CA (1) CA3137377A1 (enExample)
CL (1) CL2021002795A1 (enExample)
CO (1) CO2021014768A2 (enExample)
CR (1) CR20210559A (enExample)
DO (1) DOP2021000226A (enExample)
EA (1) EA202193038A1 (enExample)
EC (1) ECSP21082527A (enExample)
IL (1) IL287758A (enExample)
JO (1) JOP20210300A1 (enExample)
MA (1) MA55872A (enExample)
MX (1) MX2021013671A (enExample)
MY (1) MY206253A (enExample)
NZ (1) NZ780763A (enExample)
PE (1) PE20220287A1 (enExample)
PH (1) PH12021552776A1 (enExample)
SA (1) SA521430793B1 (enExample)
SG (1) SG11202110842QA (enExample)
TW (1) TWI836069B (enExample)
UA (1) UA129953C2 (enExample)
WO (1) WO2020225400A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR122266A1 (es) 2019-05-09 2022-08-31 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
US20220127344A1 (en) * 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
EP4314047A1 (en) * 2021-03-30 2024-02-07 Bayer Aktiengesellschaft Anti-sema3a antibodies and uses thereof
CN116790610B (zh) * 2023-05-18 2024-09-20 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
JP5888728B2 (ja) * 2009-11-05 2016-03-22 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
WO2013005603A1 (ja) * 2011-07-01 2013-01-10 公立大学法人横浜市立大学 結膜におけるアレルギー性炎症の予防及び／又は治療剤
US9879075B2 (en) 2013-02-06 2018-01-30 Yokohama City University and Chiome Bioscience Inc. Anti-semaphorin 3A antibody and treatment of Alzheimer's disease and inflammatory immune diseases using same
EP2958580B1 (en) * 2013-02-21 2025-12-10 RSEM, Limited Partnership Inhibition of sema3a in the prevention and treatment of ocular hyperpermeability
CA2960054C (en) * 2014-09-05 2023-11-14 Rsem, Limited Partnership Compositions and methods for treating and preventing inflammation
WO2017074013A1 (ko) 2015-10-27 2017-05-04 사회복지법인 삼성생명공익재단 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도
KR101854529B1 (ko) * 2015-10-27 2018-05-04 (주) 팬젠 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
US10604571B2 (en) 2015-10-27 2020-03-31 Samsung Life Public Welfare Foundation Antibody to human and mouse SEMA3A and use thereof
AR122266A1 (es) * 2019-05-09 2022-08-31 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares

Also Published As

Publication number Publication date
DOP2021000226A (enExample) 2021-12-15
US20240336674A1 (en) 2024-10-10
US11267880B2 (en) 2022-03-08
CN113795509A (zh) 2021-12-14
JOP20210300A1 (ar) 2023-01-30
JP7314310B2 (ja) 2023-07-25
SG11202110842QA (en) 2021-10-28
BR112021019854A2 (pt) 2022-02-15
MY206253A (en) 2024-12-05
IL287758A (en) 2022-01-01
CR20210559A (es) 2021-12-23
UA129953C2 (uk) 2025-09-24
EP3966239A1 (en) 2022-03-16
EA202193038A1 (ru) 2022-03-30
ECSP21082527A (es) 2021-12-30
AR122266A1 (es) 2022-08-31
AU2020267874A1 (en) 2021-10-28
JP7638332B2 (ja) 2025-03-03
NZ780763A (en) 2025-09-26
US20220144929A1 (en) 2022-05-12
SA521430793B1 (ar) 2024-03-28
PH12021552776A1 (en) 2022-09-19
CA3137377A1 (en) 2020-11-12
PE20220287A1 (es) 2022-02-25
CO2021014768A2 (es) 2021-11-19
CL2021002795A1 (es) 2022-08-05
MX2021013671A (es) 2021-12-10
TWI836069B (zh) 2024-03-21
TW202108621A (zh) 2021-03-01
KR20220007128A (ko) 2022-01-18
JP2023130473A (ja) 2023-09-20
WO2020225400A1 (en) 2020-11-12
US20200385446A1 (en) 2020-12-10
JP2022531698A (ja) 2022-07-08

Similar Documents

Publication Publication Date Title
EP3749264C0 (en) Laser therapy for treatment and prevention of eye diseases
MA55872A (fr) Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3829595A4 (en) MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
EP3858977A4 (en) STRAIN FOR THE PREVENTION AND TREATMENT OF METABOLIC DISEASES AND USE THEREOF
EP3829569A4 (en) SPINOSYN FORMULATIONS FOR THE TREATMENT OF DEMODEX-INDUCED EYE AND FACIAL DISORDERS
MA55325A (fr) Composés pour le traitement de maladies pd-l1
EP4045036A4 (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
EP3937932A4 (en) CGAS INHIBITORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER METASTASIS
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3573658A4 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
EP3866781A4 (en) NOVEL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP3390634A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES
EP2968470A4 (en) MODIFIED PROTEINS WITH A MÜLLERSCHEN HEMMERSUBSTANZ AND USES THEREOF FOR THE TREATMENT OF DISEASES
MA47442A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
EP3639833A4 (en) AGENTS FOR THE PREVENTION OR TREATMENT OF FAT RELATED DISEASES AND INFLAMMATION
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
EP4236944A4 (en) Bicyclic compounds and uses thereof for the treatment of diseases
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
MA45999A (fr) Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3911153A4 (en) TREATMENT OF DISEASES INVOLVING ENPP1 OR ENPP3 DEFICIENCY
MA48751A (fr) Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax
EP4043012A4 (en) Drug for treating artery-related diseases, and use thereof
EP3331356A4 (en) PROGRANULIN (PGRN) FRAGMENTS AND DERIVATIVES FOR THE TREATMENT OR AID OF LYSOSOMAL STORAGE DISEASES